Publications by authors named "H Ulutabanca"

Intramedullary schwannomas are a type of benign spinal cord tumor that originates from the Schwann cells of the nerve sheath. They are relatively rare and typically occur within the spinal cord itself, rather than in the surrounding tissue. Treatment options for cervical intramedullary schwannomas include surgical removal of the tumor, radiation therapy, and observation.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the relationship between serum markers (NFL, GFAP, t-tau) and pituitary dysfunction in adults who experienced traumatic brain injury (TBI).
  • During the acute phase, NFL levels showed significant correlations with patient outcomes like hospital stay length and hormonal changes, while GFAP and t-tau did not correlate with hormone levels.
  • One year after TBI, NFL, GFAP, and t-tau levels decreased significantly, and no hormone deficiencies were observed, indicating potential recovery but highlighting the need for more extensive research on long-term effects.
View Article and Find Full Text PDF

Aim: To present symptoms and surgical results of patients operated on with the diagnosis of tethered cord syndrome (TCS) in adulthood.

Material And Methods: In this retrospective study, 20 patients older than 18 years were evaluated. There were 17 female and 3 male patients.

View Article and Find Full Text PDF

Introduction: Traumatic brain injuries (TBIs) pose a high risk of pituitary insufficiency development in patients. We have previously reported alterations in miR-126-3p levels in sera from patients with TBI-induced pituitary deficiency.

Methods: To investigate why TBI-induced pituitary deficiency develops only in some patients and to reveal the relationship between miR-126-3p with hormone axes, we used mice that were epigenetically modified with miR-126-3p at the embryonic stage.

View Article and Find Full Text PDF

Glioblastoma multiforme (GBM) remains one of the most challenging solid cancers to treat due to its highly aggressive and drug-resistant nature. Flavopiridol is synthetic flavone that was recently approved by the FDA for the treatment of acute myeloid leukemia. Flavopiridol exhibits antiproliferative activity in several solid cancer cells and currently evaluated in clinical trials in several solid and hematological cancers.

View Article and Find Full Text PDF